Vigabatrin 35 years later — from mechanism of action to benefit–risk considerations
Mechanism of action of vigabatrin
Vigabatrin therapy for refractory complex partial seizures
Vigabatrin therapy for refractory complex partial seizures
Vigabatrin therapy for infantile spasms
Primer on visual field testing, electroretinography, and other visual assessments for patients treated with vigabatrin
Understanding and interpreting vision safety issues with vigabatrin therapy
Non-vision adverse events with vigabatrin therapy
Balancing clinical benefits of vigabatrin with its associated risk of vision loss